Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Bonefos approved as adjuvant treatment of breast cancer
February 10th, 2005
Schering AG, Germany (SCH, SHR) announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for Bonefos (clodronate), an oral non-amino bisphosphonate intended to reduce the occurrence of bone metastases in the post-surgical (adjuvant) treatment of breast cancer patients. Berlex, Inc., Schering's U.S. affiliate, plans to request a meeting with the FDA to discuss the information that is needed to obtain approval, and will submit this information as quickly as possible. "We look forward to the opportunity to meet with the FDA so we can advance the approval process," said Marc Rubin, MD, member of the Schering AG board of...
Source: Women's Health Weekly (2005-02-10)
|
